Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Active-site mTOR inhibitors augment HSV1-dICP0 infection in cancer cells via dysregulated eIF4E/4E-BP axis.

Autor: Zakaria C; Goodman Cancer Centre, Department of Biochemistry, McGill University, Montreal, Canada., Sean P; Goodman Cancer Centre, Department of Biochemistry, McGill University, Montreal, Canada., Hoang HD; Children's Hospital of Eastern Ontario Research Institute, Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario, Canada., Leroux LP; INRS Institut Armand-Frappier Research Centre, Laval, Quebec, Canada., Watson M; Children's Hospital of Eastern Ontario Research Institute, Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario, Canada., Workenhe ST; Department of Pathology and Molecular Medicine, MG DeGroote Institute for Infectious Disease, McMaster University, Hamilton, Ontario, Canada., Hearnden J; Goodman Cancer Centre, Department of Biochemistry, McGill University, Montreal, Canada., Pearl D; Goodman Cancer Centre, Department of Biochemistry, McGill University, Montreal, Canada., Truong VT; Goodman Cancer Centre, Department of Biochemistry, McGill University, Montreal, Canada., Robichaud N; Goodman Cancer Centre, Department of Biochemistry, McGill University, Montreal, Canada., Yanagiya A; Goodman Cancer Centre, Department of Biochemistry, McGill University, Montreal, Canada., Tahmasebi S; Goodman Cancer Centre, Department of Biochemistry, McGill University, Montreal, Canada., Jafarnejad SM; Goodman Cancer Centre, Department of Biochemistry, McGill University, Montreal, Canada., Jia JJ; Children's Hospital of Eastern Ontario Research Institute, Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario, Canada., Pelin A; Center for Innovative Cancer Research, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada., Diallo JS; Center for Innovative Cancer Research, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada., Le Boeuf F; Center for Innovative Cancer Research, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada., Bell JC; Center for Innovative Cancer Research, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada., Mossman KL; Department of Pathology and Molecular Medicine, MG DeGroote Institute for Infectious Disease, McMaster University, Hamilton, Ontario, Canada., Graber TE; Children's Hospital of Eastern Ontario Research Institute, Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario, Canada., Jaramillo M; INRS Institut Armand-Frappier Research Centre, Laval, Quebec, Canada., Sonenberg N; Goodman Cancer Centre, Department of Biochemistry, McGill University, Montreal, Canada., Alain T; Children's Hospital of Eastern Ontario Research Institute, Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario, Canada.

Publikováno v: PLoS pathogens [PLoS Pathog] 2018 Aug 23; Vol. 14 (8), pp. e1007264. Date of Electronic Publication: 2018 Aug 23 (Print Publication: 2018).